12 резултата
BACKGROUND OF THE INVENTION
1. Field of the Invention
It has long been known that salicylic acid has an anti-inflammatory activity. In anthranilic acid derivatives which have also an amino group of a high electron density at the ortho-position, it has been confirmed that N-phenyl-substituted
BACKGROUND OF THE PRESENT INVENTION
A great number of substances for the effective treatment of inflammatory illnesses, for example rheumatism, have been known for a long time. Since the inflammations are often chronic, the treatment with such inflammation-preventing active substances will usually
BACKGROUND OF THE PRESENT INVENTION
A great number of substances for the effective treatment of inflammatory illnesses, for example rheumatism, have been known for a long time. Since the inflammations are often chronic, the treatment with such inflammation-preventing active substances will usually
A great number of substances for the effective treatment of inflammatory illnesses, for example rheumatism, have been known for a long time. Since the inflammations are often chronic, the treatment with such inflammation-preventing active substances will usually extend over a long period of time.
BACKGROUND OF THE PRESENT INVENTION
A great number of substances for the effective treatment of inflammatory illnesses, for example rheumatism, have been known for a long time. Since the inflammations are often chronic, the treatment with such inflammation-preventing active substances will usually
BACKGROUND OF THE PRESENT INVENTION
A great number of substances for the effective treatment of inflammatory illnesses, for example rheumatism, have been known for a long time. Since the inflammations are often chronic, the treatment with such inflammation-preventing active substances will usually
FIELD OF THE INVENTION
The present invention relates to novel anthranilic acid derivatives, which are stable towards oxidation by human cytochrome P450 and are potent inhibitors of dihydroorotate dehydrogenase (DHODH), to be used for clinical treatment of autoimmune diseases, inflammatory diseases,
FIELD OF THE INVENTION
The present invention relates to novel anthranilic acid derivatives, which are stable towards oxidation by human cytochrome P450 and are potent inhibitors of dihydroorotate dehydrogenase (DHODH), to be used for clinical treatment of autoimmune diseases, inflammatory diseases,
The present invention relates to esters of flufenamic acid with alkyl salicylates having the formula (1): ##STR2## wherein R is an alkyl group, particularly comprising 1 to 4 carbon atoms. The flufenamic acid, having the formula (2), ##STR3## is a well known, non-steroidal anti-inflammatory drug, of
The present invention relates to new polyprenyl compounds having excellent medicinal effects, processes for the production thereof and pharmaceutical compositions containing same.
More particularly, the present invention relates to polyprenyl compounds of the general formula: ##STR1## wherein R
The present invention relates to new polyprenyl compounds having excellent medicinal effects, processes for the production thereof and pharmaceutical compositions containing same.
More particularly, the present invention relates to polyprenyl compounds of the general formula: ##STR1## wherein R
BACKGROUND OF THE INVENTION
The Government has rights in this invention pursuant to NIH Grants GM 33464 and NRSA GM 12274, awarded by the Department of Health and Human Services.
This invention relates to novel compounds which function as irreversible ligands for nonsteroidal antiinflammatory drug